Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Open accessPublished version of a preprint
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Based on genomic analysis, 50% of high-grade serous ovarian cancers (HGSC) are predicted to have DNA repair defects. Whether this substantial subset of HGSCs actually have functional repair defects remains unknown. Here, we devise a platform for functional profiling of DNA repair in short-term patient-derived HGSC organoids. We tested 33 organoid cultures derived from 22 patients with HGSC for defects in homologous recombination (HR) and replication fork protection. Regardless of DNA repair gene mutational status, a functional defect in HR in the organoids correlated with PARP inhibitor sensitivity. A functional defect in replication fork protection correlated with carboplatin and CHK1 and ATR inhibitor sensitivity. Our results indicate that a combination of genomic analysis and functional testing of organoids allows for the identification of targetable DNA damage repair defects. Larger numbers of patient-derived organoids must be analyzed to determine whether these assays can reproducibly predict patient response in the clinic. Significance: Patient-derived ovarian tumor organoids grow rapidly and match the tumors from which they are derived, both genetically and functionally. These organoids can be used for DNA repair profiling and therapeutic sensitivity testing and provide a rapid means of assessing targetable defects in the parent tumor, offering more suitable treatment options. Cancer Discov; 8(11); 1404–21. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1333
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“revealing strong correlations between in vitro and in vivo drug responses against cancer in the gastrointestinal tract123, bladder124, ovary125, rectum126 and pancreas127,128.”
From Human disease models in drug development (2023) · cites this paper as [125]
In the citing paper
“PDOs are a validated preclinical model to evaluate anti-cancer drug efficacy [24,25].”
From Combining Mitomycin C with inhibition of BAD phosphorylation enhances apoptotic cell death in advanced cervical cancer (2024) · cites this paper as [24]
In the citing paper
“Patient-derived organoids or tumoroids retain cellular heterogeneity and immune cells, thus are able to more strongly recapitulate a three-dimensional (3D) tumor microenvironment ex vivo compared to homogeneous cell lines (Hill et al., 2018; Kopper et al., 2019).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Hill et al., 2018
In the citing paper
“Ovarian tumoroid cultures have been established from both ascitic fluid and primary tumors, to date primarily from the more common HGSOC but also from LGSOC, MOC, OCCC, and EnOC (Hill et al., 2018; De Witte et al., 2020; Nanki et al., 2020).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Hill et al., 2018
In the citing paper
“In contrast, it has been noted that organoid propagation methods tend to be selective and result in a cell population that may not be representative of the original tumor heterogeneity and in turn, treatment response, particularly in patients who have undergone previous neoadjuvant therapy (Hill et al., 2018).”
From Three-dimensional modelling of ovarian cancer: from cell lines to organoids for discovery and personalized medicine (2022) · cites this paper as Hill et al., 2018
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 1×
“Mutations were visualized with the cBioPortal OncoPrinter script (47, 48).”
MethodIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · cited 1×
“Mutations were visualized with the cBioPortal OncoPrinter script (47, 48).”
MethodIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Mermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880 · cited 2×
“2 and Table 1), because olaparib sensitivity is a useful surrogate marker for an HR defect (7).”
BackgroundAudeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Self-citationOrganoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
Drost, J., & Clevers, H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0007-6 · Cited by 1,790 · cited 1×
“Large-scale studies of organoids, with comparison with patient outcomes, will be required to prove the utility of this model system in the clinic (18, 19, 21).”
ResultWhole–genome characterization of chemoresistant ovarian cancer
Patch, A.-M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,569 · cited 2×
“NOVEMBER 2018 CANCER DISCOVERY | 1419 Human tumors derived from several tissue types exhibit clonal heterogeneity (22, 46), and functional assays in organoids can be used to address the effects of genomic tumor heterogeneity on therapeutic response.”
BackgroundOrganoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Cited by
Items 101–200 of 457
Stossel, C., Raitses‐Gurevich, M., Atias, D., Beller, T., Gorman, Y. G., Halperin, S., Peer, E., Denroche, R. E., Zhang, A. X. W., Notta, F., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0412 · Cited by 58
“…were enriched with poor Eastern Cooperative Oncology Group performance status, multiple comorbidities, and widespread extensive metastatic disease—clinical findings that have been shown to compromise the dose intensity of doublet/ triplet chemotherapy treatment and contribute to lower OS (35, 36).”
Aldea, M., Friboulet, L., Apcher, S., Jaulin, F., Mosele, F., Sourisseau, T., Soria, J.-C., Nikolaev, S., & André, F. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101642 · Cited by 47
Giudice, E., Huang, T., Nair, J. R., Zurcher, G., McCoy, A., Nousome, D., Radke, M. R., Swisher, E. M., Lipkowitz, S., Ibanez, K. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47215-6 · Cited by 59
“However, the clinical utility of CCNE1 ampli fi cation/ overexpression as a predictive biomarker requires more investigation as some data do not support its predictive value for ATR/CHK1 inhibitors 15,20 – 22 .”
Self-citationCesari, E., Ciucci, A., Pieraccioli, M., Caggiano, C., Nero, C., Bonvissuto, D., Sillano, F., Buttarelli, M., Piermattei, A., Loverro, M., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02682-5 · Cited by 64
Single cell-derived spheroids capture the self-renewing subpopulations of metastatic ovarian cancer
Velletri, T., Villa, C. E., Cilli, D., Barzaghi, B., Lo Riso, P., Lupia, M., Luongo, R., López-Tobón, A., De Simone, M., Bonnal, R. J. P., et al. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-021-00878-w · Cited by 48
Biegała, Ł., Gajek, A., Marczak, A., & Rogalska, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188633 · Cited by 55
Update on Emerging Therapies for Advanced Colorectal Cancer
Alese, O. B., Wu, C. S.-Y., Chapin, W. J., Ulanja, M. B., Zheng-Lin, B., Amankwah, M., & Eads, J. R. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_389574 · Cited by 55
The anticancer activity of an air-stable Pd( i )-NHC (NHC = N-heterocyclic carbene) dimer
Scattolin, T., Bortolamiol, E., Palazzolo, S., Caligiuri, I., Perin, T., Canzonieri, V., Demitri, N., Rizzolio, F., Cavallo, L., Dereli, B., et al. (2020) · Chemical Communications · doi:10.1039/d0cc03883k · Cited by 53
Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets
da Costa, A. A. B. A., & Baiocchi, G. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.10.016 · Cited by 55
Living biobank-based cancer organoids: prospects and challenges in cancer research
Li, H., Liu, H., & Chen, K. (2022) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0621 · Cited by 55
PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues
Murthy, P., & Muggia, F. M. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.002 · Cited by 58
“Interestingly, Hill et al.([66]) evaluated patient-derived ovarian cancer organoids, and found that a functional defect in HR in the organoids correlated with PARP inhibitor sensitivity, whereas a functional defect in replication fork protection correlated more strongly with carboplatin sensitivity.”
BackgroundHuman-Derived Model Systems in Gynecological Cancer Research
Lõhmussaar, K., Boretto, M., & Clevers, H. C. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.07.007 · Cited by 51
Hong, D. S., Moore, K. N., Bendell, J. C., Karp, D. D., Wang, J. S.-Z., Ulahannan, S. V., Jones, S. F., Wu, W., Donoho, G. P., Ding, Y. P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3242 · Cited by 45
ATR protects ongoing and newly assembled DNA replication forks through distinct mechanisms
Leung, W., Simoneau, A., Saxena, S., Jackson, J., Patel, P. S., Limbu, M., Vindigni, A., & Zou, L. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112792 · Cited by 56
“25,27 In 61–63 However, in contrast to HU, PARPi prevents the accumulation of reversed forks, 64 raising a question as to whether the fork protection defects of BRCA1/2-deficient cells in HU are relevant in PARPi.”
Wang, J., Chen, C., Wang, L., Xie, M., Ge, X., Wu, S., He, Y., Mou, X., Ye, C., & Sun, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.872531 · Cited by 52
“Currently, tumor organoid biobanks have been established from various types of cancer, including breast (17), lung (22, 23), colorectum (24–28), stomach (29–31), liver (32, 33), pancreas (34), ovary (35, 36), prostate (37), and brain (38).”
BackgroundMiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
Sun, C., Cao, W., Qiu, C., Li, C., Dongol, S., Zhang, Z., Dong, R., Song, K., Yang, X., Zhang, Q., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-0844-0 · Cited by 43
Scuto, M. C., Salinaro, A. T., Caligiuri, I., Ontario, M. L., Greco, V., Sciuto, N., Crea, R., Calabrese, E. J., Rizzolio, F., Canzonieri, V., et al. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111551 · Cited by 49
Li, J., Xu, H., Zhang, L., Song, L., Feng, D., Peng, X., Wu, M., Zou, Y., Wang, B., Zhan, L., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03004-z · Cited by 52
Ciucci, A., Buttarelli, M., Fagotti, A., Scambia, G., & Gallo, D. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04395-y · Cited by 51
“First published data illustrated organoid cultures obtained from few EOC patients [55, 56] and/or short-term HGSOC organoids [57].”
BackgroundFlorent, R., Weiswald, L., Lambert, B., Brotin, É., Abeilard, E., Louis, M.-H., Babin, G., Poulain, L., & N’Diaye, M. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2588-8 · Cited by 47
Granchi, C., Bononi, G., Ferrisi, R., Gori, E., Mantini, G., Glasmacher, S., Poli, G., Palazzolo, S., Caligiuri, I., Rizzolio, F., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112857 · Cited by 46
A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade
Ngoi, N. Y. L., Peng, G., & Yap, T. A. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042320-025136 · Cited by 46
Organoids: opportunities and challenges of cancer therapy
Jiang, X., Oyang, L., Qiu, P., Liu, Q., Xu, X., Wu, N., Tan, S., Yang, W., Han, Y., Lin, J., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1232528 · Cited by 47
“Currently, there were several methods to culture ovarian cancer organoids, but the highest success rate was achieved by using a combination of matrix gel and Advanced DMEM/F12 basal medium supplemented with Glutamax, B27, Nicotinamide, EGF, FGF2, FGF10, A83-01, N-acetylcysteine, Noggin, Rspondin1, p38 inhibitor, Hydro…”
BackgroundMethodTranslation Potential and Challenges of In Vitro and Murine Models in Cancer Clinic
Long, Y., Xie, B., Shen, H. C., & Wen, D. (2022) · Cells · doi:10.3390/cells11233868 · Cited by 47
Organoids of epithelial ovarian cancer as an emerging preclinical in vitro tool: a review
Dumont, S., Jan, Ž., Heremans, R., Gorp, T. V., Vergote, I. B., & Timmerman, D. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0577-2 · Cited by 43
Yang, J., Huang, S., Cheng, S., Jin, Y., Zhang, N., & Wang, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.701429 · Cited by 42
Patient-derived Tumour Organoids: A Bridge between Cancer Biology and Personalised Therapy
Wu, W., Li, X., & Yu, S. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.04.050 · Cited by 43
Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches
Guffanti, F., Mengoli, I., & Damia, G. L. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1405361 · Cited by 49
Organoid models in gynaecological oncology research
Semertzidou, A., Brosens, J. J., McNeish, I. A., & Kyrgiou, M. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102103 · Cited by 44
Chiang, Y., Lin, P., & Cheng, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.675972 · Cited by 41
Scattolin, T., Pessotto, I., Cavarzerani, E., Canzonieri, V., Orian, L., Demitri, N., Schmidt, C., Casini, A., Bortolamiol, E., Visentin, F., et al. (2022) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.202200103 · Cited by 47
Tao, M., Sun, F., Wang, J., Wang, Y., Zhu, H., Chen, M., Liu, L., Liu, L., Lin, H., & Wu, X. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106232 · Cited by 40
Lee, T. W., Lai, A., Harms, J. K., Singleton, D. C., Dickson, B. D., Macann, A., Hay, M. P., & Jamieson, S. M. F. (2020) · Cancers · doi:10.3390/cancers12123743 · Cited by 40
Färkkilä, A., Rodríguez, A., Oikkonen, J., Gulhan, D., Nguyen, H. Q., Domínguez, J., Ramos, S., Mills, C. E., Pérez‐Villatoro, F., Lazaro, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2912 · Cited by 45
“We next studied tumor samples from a patient with BRCA1deficient HGSC and acquired resistance to PARPi (37), and explored whether clonal evolutionary patterns existed during the acquisition of PARPi resistance.”
BackgroundSelf-citationDecellularized normal and cancer tissues as tools for cancer research
Gentilin, E., D’Angelo, E., Agostini, M., & Astolfi, L. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00398-2 · Cited by 39
“To date, living biobanks of patientspecific organoids derived from cancer tissues have been established, among which breast [47], prostate [48], pancreatic [49–51], colorectal [47, 52, 53], ovarian [54, 55], bladder [56], liver [57], lung [58, 59], esophagus [60], endometrium [61] and brain [62], and the uses of dECM…”
Backgroundvan Wijk, L. M., Nilas, A. B., Vrieling, H., & Vreeswijk, M. P. G. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2020102 · Cited by 46
Ovejero-Sánchez, M., González‐Sarmiento, R., & Herrero, A. B. (2023) · Cancers · doi:10.3390/cancers15020448 · Cited by 40
Spagnol, G., Sensi, F., Tommasi, O. D., Marchetti, M., Bonaldo, G., Xhindoli, L., Noventa, M., Agostini, M., Tozzi, R., & Saccardi, C. (2023) · Cancers · doi:10.3390/cancers15072059 · Cited by 42
“Hill 2018 [32] Ovaries Omentum Pleural effusion Mesentery Diaphragm HGSC LGSC 22 33 80–90% WES 98.”
BackgroundMethodInfluentialTao, M., & Wu, X. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02139-7 · Cited by 40
“These PDOs have well preserved the original tumor histological and genetic characteristics and can be used for drug sensitivity testing and DNA repair functional assays [110].”
BackgroundInfluentialOrganoids of the Female Reproductive Tract: Innovative Tools to Study Desired to Unwelcome Processes
Heremans, R., Jan, Ž., Timmerman, D., & Vankelecom, H. E. J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.661472 · Cited by 41
“Organoids were amenable to geneediting, xenografting and drug-sensitivity profiling (Hill et al., 2018; Kopper et al., 2019; Maru et al., 2019b; Phan et al., 2019; Chen et al., 2020; Hoffmann et al., 2020; Lõhmussaar et al., 2020; Maenhoudt et al., 2020).”
BackgroundMethodInfluentialHigh-grade serous ovarian carcinoma organoids as models of chromosomal instability
Vias, M., Gavarró, L. M., Sauer, C. M., Sanders, D. A., Piskorz, A., Couturier, D., Ballereau, S. J., Hernando, B., Schneider, M. P., Hall, J. A. M., et al. (2023) · eLife · doi:10.7554/elife.83867 · Cited by 40
Iron nitroprusside as a chemodynamic agent and inducer of ferroptosis for ovarian cancer therapy
Asif, K., Adeel, M., Rahman, M. M., Caligiuri, I., Perin, T., Čemažar, M., Canzonieri, V., & Rizzolio, F. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02691k · Cited by 35
Benada, J., Bulanova, D. R., Azzoni, V., Petrosius, V., Ghazanfar, S., Wennerberg, K., & Sørensen, C. S. (2023) · NAR Cancer · doi:10.1093/narcan/zcad029 · Cited by 37
Górski, J., Zhang, Z., McCorkle, J. R., DeJohn, J., Wang, C., Miller, R. W., Gallion, H. H., Dietrich, C. S., Ueland, F. R., & Kolesar, J. (2021) · Biomedicines · doi:10.3390/biomedicines9081021 · Cited by 38
“Fresh ovarian tumor tissue was obtained from patients at the time of debulking surgery, dissociated into a single ovarian cancer cell suspension, and established in Matrigel® Growth Factor Reduced Basement Membrane Matrix (Corning) in vitro using factor-defined media [14,15].”
MethodMiller, R. E., Elyashiv, O., El-Shakankery, K. H., & Ledermann, J. A. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s272199 · Cited by 36
“Preclinically, reduced DNA damaged induced nuclear RAD51 foci has been associated with BRCA1/2 mutations in addition to response to PARPi in both ovarian and breast cancer models and in small numbers of patient samples.(65,66) Although measuring reduced RAD51 foci as a surrogate for HRD holds promise, translating a re…”
BackgroundZhang, N., Tian, Y., Zhou, L., Li, M., Chen, H., Song, S., Huan, X., Bao, X., Zhang, A., Miao, Z., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03475-4 · Cited by 42
Vernon, M., Lambert, B., Meryet‐Figuière, M., Brotin, É., Weiswald, L., Paysant, H., Vigneron, N., Wambecke, A., Abeilard, E., Giffard, F., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0510 · Cited by 36
“It would therefore be interesting to study the importance of BIM expression as a predictive factor in the success of such strategies in PDOs, as they have recently emerged as preclinical models of patient responses to drugs in clinical practice (33–36), including in ovarian carcinoma (37, 38).”
BackgroundAbreu, S., Silva, F., Mendes, R., Mendes, T. F., Teixeira, M., Santo, V. E., Boghaert, E. R., Félix, A., & Brito, C. (2020) · Scientific Reports · doi:10.1038/s41598-020-76291-z · Cited by 31
Manic, G., Musella, M., Corradi, F., Sistigu, A., Vitale, S., Rehim, S. S. A., Mattiello, L., Malacaria, E., Galassi, C., Signore, M., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-020-00733-4 · Cited by 31
Kinase Inhibitors in the Treatment of Ovarian Cancer: Current State and Future Promises
Skorda, A., Bay, M. L., Hautaniemi, S., Lahtinen, A., & Kallunki, T. (2022) · Cancers · doi:10.3390/cancers14246257 · Cited by 35
“[133] Prexasertib CHEK1 Carboplatin, Gemcitabine HGSC short-term organoid culture (n = 10) Sesitive for fork-unstable organoids.”
BackgroundAsif, K., Adeel, M., Rahman, M. M., Sfriso, A., Bartoletti, M., Canzonieri, V., Rizzolio, F., & Caligiuri, I. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.03.005 · Cited by 32
“Cancer organoids are a useful ex vivo platform to determine therapeutic drugs efficacy [82–84] that mimic the response of patients in clinic [85].”
BackgroundComparative analysis of syngeneic mouse models of high-grade serous ovarian cancer
Cook, D. P., Galpin, K. J. C., Rodriguez, G. M., Shakfa, N., Wilson‐Sanchez, J., Echaibi, M., Pereira, M., Matuszewska, K., Haagsma, J., Murshed, H., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05529-z · Cited by 41
Page, C. L., Amuzu, S., Rahimi, K., Gotlieb, W. H., Ragoussis, J., & Tonin, P. N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.005 · Cited by 30
Lipogenesis promotes mitochondrial fusion and maintains cancer stemness in human NSCLC
Liu, Z., Lei, J., Wu, T., Hu, W., Zheng, M., Wang, Y., Song, J., Ruan, H., Xu, L., Ren, T., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.158429 · Cited by 35
“shown a spectrum of responses to conventional and investigational drugs, and these responses essentially mimic the reaction of those patients to the same agents (42, 43).”
BackgroundRavindranathan, R., Somuncu, O., da Costa, A. A. B. A., Mukkavalli, S., Lamarre, B. P., Nguyen, H. Q., Grochala, C., Jiao, Y., Liu, J. F., Kochupurakkal, B. S., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2413954121 · Cited by 33
“PDOs provide a useful model system for rapid functional testing and prediction of drug sensitivity (61–63).”
InfluentialSelf-citationSingle-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity
da Costa, A. A. B. A., Somuncu, O., Ravindranathan, R., Mukkavalli, S., Martignetti, D. B., Nguyen, H. Q., Jiao, Y., Lamarre, B. P., Sadatrezaei, G., Moreau, L. A., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-4007 · Cited by 34
“Therapeutic drug responses in fresh human tumor organoid models correlate, at least in part, with the corresponding patient responses in the clinic (38, 47, 48).”
Self-citationExploiting replicative stress in gynecological cancers as a therapeutic strategy
Ngoi, N. Y. L., Sundararajan, V., & Tan, D. S. P. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001277 · Cited by 29
Sheta, R., Bachvarova, M., Plante, M., Renaud, M., Sebastianelli, A., Gregoire, J., Navarro, J. M., Bringas, R., Masson, J., & Bachvarov, D. R. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02613-4 · Cited by 29
Morice, P., Coquan, E., Weiswald, L., Lambert, B., Vaur, D., & Poulain, L. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01295-z · Cited by 29
“In another study eight out of 33 ovarian cancer models were identified to have an HRD-associated mutational signature potentially predictive of PARPi sensitivity but, notably, only two of these models (6%) were considered to be olaparib sensitive based on functional assay.(48) In breast cancer organoid models, a high…”
BackgroundMiyabayashi, K., Nakagawa, H., & Koike, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682872 · Cited by 35
“The organoid culture system is a powerful tool for personalized medicine and is used in co-clinical trials because the response of PDOs to drugs largely mimics the initial response of corresponding patients to the same drugs (24, 108, 111, 117, 118) (Figure 2).”
MethodHarnessing preclinical models for the interrogation of ovarian cancer
Qin, T., Fan, J., Lu, F., Zhang, L., Liu, C., Xiong, Q., Zhao, Y., Chen, G., & Sun, C. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02486-z · Cited by 32
“innovatively reported a short-term cultured OC platform to identify targetable DNA damage repair defects in parent tumors [114].”
BackgroundInfluentialEmerging functions of Fanconi anemia genes in replication fork protection pathways
Kolinjivadi, A. M., Crismani, W., & Ngeow, J. Y. Y. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa087 · Cited by 32
Crosstalk of T cells within the ovarian cancer microenvironment
Chap, B. S., Rayroux, N., Grimm, A. J., Ghisoni, E., & Laniti, D. D. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.09.001 · Cited by 37
Goss, K. L., Koppenhafer, S. L., Waters, T. W., Terry, W. W., Wen, K., Wu, M., Ostergaard, J., Gordon, P. M., & Gordon, D. J. (2020) · Oncogene · doi:10.1038/s41388-020-01552-0 · Cited by 30
Tumor Organoid and Spheroid Models for Cervical Cancer
Kutle, I., Polten, R., Hachenberg, J., Klapdor, R., Morgan, M. A., & Schambach, A. (2023) · Cancers · doi:10.3390/cancers15092518 · Cited by 33
Gupta, N., Huang, T., Nair, J. R., An, D., Zurcher, G., Lampert, E. J., McCoy, A., Cimino‐Mathews, A., Swisher, E. M., Radke, M. R., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add7872 · Cited by 27
“But recent clinical studies have shown that CCNE1 overexpression or copy number gain alone might not predict the sensitivity to cell cycle checkpoint blockade (30, 48).”
BackgroundSelf-citationAnderle, N., Koch, A., Gierke, B., Keller, A., Staebler, A., Hartkopf, A. D., Brucker, S. Y., Pawlak, M., Schenke‐Layland, K., & Schmees, C. (2022) · Cancers · doi:10.3390/cancers14122895 · Cited by 29
Chiappa, M., Guffanti, F., Anselmi, M., Lupi, M., Panini, N., Wiesmüller, L., & Damia, G. L. M. (2022) · Cancers · doi:10.3390/cancers14071807 · Cited by 29
Ovarian cancer: Diagnosis and treatment strategies (Review)
Li, X., Zhuo-cheng, L., Ma, H., Li, X., Zhai, H., Li, X., Cheng, X., Zhao, X., Zhao, Z., & Hao, Z. (2024) · Oncology Letters · doi:10.3892/ol.2024.14574 · Cited by 39
“Patient‑derived organoids (PDOs) have been recognized as an effective tumor model for the screening of PARP inhibitors and for addressing drug resistance in ovarian cancer, with patients experiencing improved results when treated according to recommendations derived from these models (78,79).”
Patient-Derived Organoids: A Game-Changer in Personalized Cancer Medicine
Abbasian, M. H., Sobhani, N., Sisakht, M. M., D’Angelo, A., Sirico, M., & Roudi, R. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10805-4 · Cited by 29
“Addition - ally, the overall copy number and allelic imbalance across the genome were comparable between the organoids and original tumors [76].”
Shah, B. A., Hussain, M. S., & Seth, A. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47080638 · Cited by 31
In Situ Vitrification of Lung Cancer Organoids on a Microwell Array
Liu, Q., Zhao, T., Wang, X., Chen, Z., Hu, Y., & Chen, X. (2021) · Micromachines · doi:10.3390/mi12060624 · Cited by 29
“PDOs can be established from many different types of tumor tissues, including colorectal cancers [2], breast cancers [3], lung cancers [4], ovary cancers [5], etc.”
BackgroundApplication Progress of Organoids in Colorectal Cancer
Luo, L., Ma, Y., Zheng, Y., Su, J., & Huang, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.815067 · Cited by 35
“Drug Discovery Drugs sensitivity and treatment strategies were tested with the variety of patient-derived tumor organoids with genetic diversity and tumor heterogeneity, and the results were highly consistent with the clinical response of the patient to the corresponding drugs and treatment strategies (Pauli et al., 2…”
ResultPARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components
Coyne, G. O., Karlovich, C., Wilsker, D. F., Voth, A. R., Parchment, R. E., Chen, A. P., & Doroshow, J. H. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s278092 · Cited by 25
“Hill et al reported that while genomics assays alone could not predict therapeutic response, a combination of genomic and functional HR deficiency assays correlated with sensitivity to PARPi in organoids derived from high-grade serous ovarian cancers.(80) This platform may provide an alternative method of assessing HR…”
MethodThe Roles of Extracellular Vesicles and Organoid Models in Female Reproductive Physiology
Thompson, R. E., Bouma, G. J., & Hollinshead, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063186 · Cited by 30
Cancer organoid applications to investigate chemotherapy resistance
Harada, K., & Sakamoto, N. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1067207 · Cited by 27
“It was also noted that the clinical outcome was largely consistent with the results of susceptibility testing to other anticancer drugs (Hill et al., 2018).”
ResultPaola, F. J. D., Calafato, G., Piccaluga, P. P., Tallini, G., & Rhoden, K. J. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15080394 · Cited by 27
“Ovarian carcinoma-PDOs can be efficiently cultured without Wnt3A in a basal medium supplemented with R-spondin 1, noggin, EGF, FGF-10, FGF2, nicotinamide, N-acetylcysteine, prostaglandin E2, SB202190 and A83–01 [73].”
Zeng, L., Liao, Q., Zhao, H., Jiang, S., Yang, X., Tang, H., He, Q., Yang, X., Fang, S., He, J., et al. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0566 · Cited by 24
Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma
Wong, O. G., Li, J., & Cheung, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.666815 · Cited by 25
“Recently, short-term patient-derived ovarian cancer organoids have been proposed to serve as testing platformof real-time HR deficiency and PARPi sensitivity, capable of supplementing sequencing-based approaches (70).”
BackgroundNext generation patient derived tumor organoids
Podaza, E., Kuo, H., Nguyen, J., Elemento, O., & Martín, M. L. (2022) · Translational research · doi:10.1016/j.trsl.2022.08.003 · Cited by 27
Murumägi, A., Ungureanu, D., Khan, S. A., Arjama, M., Välimäki, K. E., Ianevski, A., Ianevski, P., Bergström, R., Dini, A., Kanerva, A., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02067-z · Cited by 29
“For example, organoid models are intensively investigated as advanced models, but their suitability for real-time translational application and for highthroughput drug screening purposes is limited by the time needed to establish and expand such models [12, 13].”
BackgroundLandon‐Brace, N., Li, N. T., & McGuigan, A. P. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300903 · Cited by 28
Varinelli, L., Battistessa, D., Guagliò, M., Zanutto, S., Illescas, O., Lorenc, E., Pisati, F., Kusamura, S., Cattaneo, L., Sabella, G., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03052-5 · Cited by 24
Xie, T., Dickson, K.-A., Yee, C., Ma, Y., Ford, C. E., Bowden, N. A., & Marsh, D. J. (2022) · Cancers · doi:10.3390/cancers14194621 · Cited by 28
Integration of Organoids With CRISPR Screens: A Narrative Review
Mukhare, R., Gandhi, K., Kadam, A., Raja, A., Singh, A., Madhav, M., Chaubal, R., Pandey, S., & Gupta, S. (2025) · Biology of the Cell · doi:10.1111/boc.70006 · Cited by 30
Tzouras, N. V., Scattolin, T., Gobbo, A., Bhandary, S., Rizzolio, F., Cavarzerani, E., Canzonieri, V., Hecke, K. V., Vougioukalakis, G. C., Cazin, C. S. J., et al. (2022) · ChemMedChem · doi:10.1002/cmdc.202200135 · Cited by 26
Genomic and Epigenomic Characterization of Tumor Organoid Models
Nam, C., Ziman, B., Sheth, M., Zhao, H., & Lin, D. (2022) · Cancers · doi:10.3390/cancers14174090 · Cited by 25
“On the other hand, gemcitabine killed Trp53−/−; Ccne1OE; Akt2OE; KrasOE organoids more effectively than the other models, consistent with the previous finding linking CCNE1 overexpression to DNA replication stress [15,16].”
BackgroundPatrício, D., Santiago, J., Mano, J. F., & Fardilha, M. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1590 · Cited by 28
Horst, E. N., Bregenzer, M. E., Mehta, P., Snyder, C. S., Repetto, T., Yang‐Hartwich, Y., & Mehta, G. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.04.041 · Cited by 27
Zhang, L., Zhao, J., Su, C., Wu, J., Jiang, L., Chi, H., & Wang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1573686 · Cited by 29
Predictive Potential of Head and Neck Squamous Cell Carcinoma Organoids
Hill, S. J., & D’Andrea, A. D. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0527 · Cited by 23
Self-citationExperimental models for ovarian cancer research
Tsang, S. I., Hassan, A. A., To, S. K. Y., & Wong, A. S. T. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113150 · Cited by 26
Pacheco-Barcía, V., Martín, A. J. M., Castro, E., Ballesteros, A. I., Marquina, G., González-Díaz, I., Colomer, R., & Romero-Laorden, N. (2022) · Cancers · doi:10.3390/cancers14122950 · Cited by 26
“Reduced, DNA-damaged, induced nuclear RAD51 foci have been associated with BRCA1 or BRCA2 gene defects and PARPi responses [110,111].”
BackgroundA Protocol for Organoids from the Urine of Bladder Cancer Patients
Walz, S., Pollehne, P., Geng, R., Schneider, J., Maas, M., Aicher, W. K., Stenzl, A., Amend, B., & Harland, N. (2023) · Cells · doi:10.3390/cells12172188 · Cited by 25
Tseng, Y., & Boehm, J. S. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.02.007 · Cited by 21
Salivary gland regeneration: from salivary gland stem cells to three-dimensional bioprinting
Phan, T. V., Oo, Y., Ahmed, K., Rodboon, T., Rosa, V., Yodmuang, S., & Ferreira, J. N. (2023) · SLAS TECHNOLOGY · doi:10.1016/j.slast.2023.03.004 · Cited by 25
Lavudi, K., Banerjee, A. T., Li, N., Yang, Y., Cai, S., Bai, X., Zhang, X., Li, A., Wani, E., Yang, S., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00411-x · Cited by 30
“To test the effect of NCT-505 on PARPi sensitivity in primary tumor cells, we collected a panel of freshly removed HGSOC tumor tissues and generated Patient-derived organoids (PDOs) according to a published protocol 26 .”
In vitro drug testing using patient-derived ovarian cancer organoids
Chen, L., Chou, Y.-T., Liew, P., Chu, L.-H., Wen, K., Lin, S., Weng, Y., Wang, H.-C., Su, P., & Lai, H. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-024-01520-2 · Cited by 27
“A few studies have applied DNA repair inhibitors (PARP inhibitor rucaparib) to OV-PDOs, showing the capability of organoids as a drug test model for targeted therapies [16, 17].”
Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment
McDowell, A., Hill, K. S., McCorkle, J. R., Górski, J., Zhang, Y., Salahudeen, A. A., Ueland, F. R., & Kolesar, J. (2021) · Diagnostics · doi:10.3390/diagnostics11030395 · Cited by 22
Psilopatis, I., Sykaras, A. G., Mandrakis, G., Vrettou, K., & Theocharis, S. E. (2022) · Biomedicines · doi:10.3390/biomedicines11010001 · Cited by 24
Metadata
- Authors
- Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., Yang, C., Morizane, R., Kochupurakkal, B. S., Do, K. T., Konstantinopoulos, P. A., Liu, J. F., Bonventre, J. V., Matulonis, U. A., Shapiro, G. I., Berkowitz, R. S., Crum, C. P., & D'Andrea, A. D.
- Affiliations
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of Washington (US)
- Dana-Farber Cancer Institute (US)
- 1Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
- ORCID
- Hill, Sarah J.
- Decker, Brennan
- Roberts, Emma A.
- Horowitz, Neil S.
- Worley, Michael J.
- Feltmate, Colleen M.
- Nucci, Marisa R.
- Swisher, Elizabeth M.
- Nguyen, Huy
- Yang, Chunyu
- Morizane, Ryuji
- Kochupurakkal, Bose S.
- Do, Khanh T.
- Konstantinopoulos, Panagiotis A.
- Liu, Joyce F.
- Bonventre, Joseph V.
- Matulonis, Ursula A.
- Shapiro, Geoffrey I.
- Berkowitz, Ross S.
- Crum, Christopher P.
- Venue
- Cancer Discovery
- Published
- 2018-11-01
- Volume
- 8
- Issue
- 11
- Pages
- 1404-1421
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6365285
- OpenAlex
- W2891058330
- Cited by
- 452
- References
- 49
- Citations by year
- 2026: 37 · 2025: 43 · 2024: 67 · 2023: 78 · 2022: 66 · 2021: 72 · 2020: 63 · 2019: 25 · 2018: 1
- FWCI
- 15.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Stand Up to Cancer (SU2C) (SU2C-AACR-DT16-15)
- HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) (R37HL052725, P01HL048546)
- U.S. Department of Defense (DOD) (BC151331P1)
- Leukemia and Lymphoma Society (LLS) (6237-13)
- Breast Cancer Research Foundation (BCRF)
- Richard and Susan Smith Family Foundation
- The Bridge Project
- HHS | NIH | National Cancer Institute (NCI) (UM1 CA186709)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- high-grade serous ovarian cancer, DNA repair deficiency, patient-derived tumor organoids, homologous recombination deficiency, replication fork protection, PARP inhibitor sensitivity, carboplatin sensitivity, CHK1 inhibitor, ATR inhibitors, predictive biomarkers, targeted therapy
- MeSH terms
- Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, DNA Repair, DNA Replication, Female, Follow-Up Studies, Humans, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Organ Culture Techniques, Organoids, Ovarian Neoplasms, Prognosis, Pyrazines, Pyrazoles, Biomarkers, Tumor, Carboplatin, Cystadenocarcinoma, Serous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.